Last reviewed · How we verify
NCT05682612
Prognostic Value of PtcO2 in Patients With COVID-19
trial testing outcome in COVID-19 Acute Respiratory Distress Syndrome in 40 participants. Status unknown.
1 December 2023
Quick facts
| Lead sponsor | Southeast University, China |
|---|---|
| Status | Status unknown |
| Study type | OBSERVATIONAL |
| Enrollment | 40 |
| Start date | 9 January 2023 |
| Primary completion | 1 December 2023 |
| Estimated completion | 30 December 2023 |
| Sites | 1 location across China |
Drugs / interventions tested
- outcome
- Subtype of COVID-19
Conditions studied
- COVID-19 Acute Respiratory Distress Syndrome — all drugs for COVID-19 Acute Respiratory Distress Syndrome →
Sponsor
Southeast University, China
Who can join
Adults 18 to 80, any sex, with COVID-19 Acute Respiratory Distress Syndrome. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
Five percent of patients with COVID-19 progressed to respiratory failure and required ICU admission, such patients often have abnormal oxygen tolerance. However, there is still a lack of clinical indicators to predict the prognosis and treatment responsiveness of COVID-19.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT05682612
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of outcome
Trials testing the same drug.
- NCT03345758 — Long Term Outcome of Extracorporeal Membrane Oxygenation Patients in China · unknown
Other recruiting trials for COVID-19 Acute Respiratory Distress Syndrome
Currently open trials in the same condition.
- NCT06402318 — Passive Detection- SARS-CoV-2 (COVID-19) A&M Breathalyzer (PROTECT Kiosk) for Operational Medicine · recruiting
- NCT05765396 — SARS-CoV-2/COVID-19 Study of Next Generation Non-Invasive Passive Detection Technologies · active not recruiting
- NCT04964115 — Post Acute Sequelae of COVID-19 · active not recruiting
- NCT05164744 — Cardiac Magnetic Resonance Tissue Characterization in COVID-19 Survivors · recruiting
- NCT04896853 — Treatment of Respiratory Complications Associated With COVID19,Influenza ,Metapneumovirus,RSV Infection Using ProTrans® · Phase 1 · active not recruiting
Other Southeast University, China trials
Trials by the same sponsor.
- NCT07519512 — Effect of Early Transition to Assisted Ventilation on 28-day Successful Extubation in Critically Ill Patients · NA · recruiting
- NCT06990477 — Effect of EIT-guided PEEP in ARDS Patients With Higher Recruitability · NA · recruiting
- NCT07362537 — Enteral Nutrition Delivery in Prone Position Ventilated Patients With Moderate to Severe ARDS · NA · recruiting
- NCT07327268 — Cyclic On-off Switching of Pulmonary Blood Flow in Moderate to Severe ARDS · not yet recruiting
- NCT07284888 — Practices of Prone Positioning Ventilation in Patients With Moderate-to-Severe ARDS in Intensive Care Units: A Registry- · recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT05682612 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Southeast University, China
- Last refreshed: 12 October 2023
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05682612.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing